Deal Watch: Endo Elbows In On Valeant’s Pursuit Of Salix
Bristol options rights to investigational prostate cancer immunotherapy, giving Bavarian Nordic additional funding to develop the candidate. Targacept finally calls it a day, in a reverse merger with Catalyst, while Arrowhead buys out the RNAi assets of Novartis.
You may also be interested in...
Roche paying $450 million for Danish biotech Santaris is likely to fuel excitement around RNA-targeting technologies and may generate a liquidity boost for Europe’s VC sector.
While planning to split into two companies, one focused on its successful hemophilia franchise, Baxter fully acquires Phase I/II gene therapy program for hemophilia B. Baxter has been seeking ways to bolster its hemophilia business in the face of coming competition from the likes of Biogen Idec.
Former Valeant President De Silva joins Endo in the midst of a challenging year for the company, as two top-selling drugs face generic competition. De Silva will need to reenergize Endo and do so quickly if he is to maintain the early favor he appears to have won from investors.